Comparing the current results to its competitors, Crescent Biopharma Inc reported Revenue increase in the 2 quarter 2026 by 0 % year on year. The revenue growth was below Crescent Biopharma Inc 's competitors' average revenue growth of 109.68 %, achieved in the same quarter.
Crescent Biopharma Inc 's Comment on Competition and Industry Peers
The company integrates the functional properties of ivonescimab with a proprietary molecule in its product development. Its candidate, CR-001, may benefit from clinical results associated with ivonescimab, potentially accelerating development timelines and reducing patient enrollment in late-stage trials. The biotechnology and biopharmaceutical industries involve continuous technological advancement and competition from major pharmaceutical and biotechnology companies, academic institutions, governmental agencies, and public and private research organizations. Competitors often possess greater financial resources and expertise in research and development, manufacturing, clinical trials, regulatory approvals, and marketing. Industry mergers and acquisitions may further enhance competitor resources.
November 4, 2025
Crescent Biopharma s CR-001: A Promising New Approach in Cancer Immunotherapy In the evolving landscape of cancer immunotherapy, Crescent Biopharma Inc. has made a notable advancement with their investigational bispecific antibody, CR-001. The company is set to present compelling preclinical data at the 40th Annual Meeting of the Society for Immunotherapy of Cancers (SITC), providing insight into the potential of CR-001 as a novel therapeutic option for patients with solid tumors. This announcement underscores Crescent Biopharma s commitment to innovative cancer treatment and sets a promising tone for the future of oncology. What is CR-001CR-001 is a bispecific antibody designed to target two critical pathwa...
Galectin Therapeutics Inc is a biotechnology company that focuses on developing therapies for fibrotic diseases and cancer by targeting galectin proteins. Their business model involves conducting research and development to create novel galectin-targeting drugs, partnering with pharmaceutical companies for joint development and commercialization, and potentially seeking regulatory approval for their products to enter the market. They generate revenue through licensing agreements, collaborations, and potential sales of their developed therapies.
Lantern Pharma Inc's business model focuses on leveraging artificial intelligence and machine learning to identify and repurpose existing drugs for the treatment of various diseases.
Oncotelic Therapeutics Inc is a biotechnology company that focuses on developing and commercializing novel therapeutics for the treatment of cancer. Their business model revolves around conducting research to develop innovative drugs and therapies, and subsequently bringing those products to market to generate revenue and improve patient outcomes in cancer treatment.
Phathom Pharmaceuticals Inc is a biopharmaceutical company that focuses on developing treatments for gastrointestinal diseases. Their business model involves advancing their pipeline of drug candidates through research and development, and seeking regulatory approval for commercialization. By strategically targeting unmet medical needs in the gastrointestinal space, Phathom Pharmaceuticals aims to provide innovative solutions to improve patient outcomes.
Puretech Health Plc is a biotechnology company that operates a unique business model focusing on innovation and entrepreneurship. They identify and validate disruptive technologies and build and invest in companies around those technologies, with a focus on identifying unmet medical needs. By developing a diversified portfolio of cutting-edge healthcare companies, Puretech aims to deliver breakthrough therapies to improve patient outcomes.
Sources:
Crescent Biopharma Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Crescent Biopharma Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
